Abstract WEAB0302–Table 1.
Effect of Coadministration on HIV ARVs and SOF/VEL
| ARV with SOF/VEL | Effect on SOF/VEL AUC | Effect on ARV AUC |
|---|---|---|
| EFV/FTC/TDF | SOF: ↔ GS-331007: ↔ VEL: ↓53% | EFV: ↔ FTC: ↔ TFV: ↑81% |
| FTC/RPV/TDF | SOF: ↔ GS-331007: ↔ VEL: ↔ | FTC: ↔ RPV: ↔ TFV: ↑40% |
| DTG | SOF: ↔ GS-331007: ↔ VEL: ↔ | DTG: ↔ |
| RAL+FTC/TDF | SOF: ↔ GS-331007: ↔ VEL: ↔ | RAL: ↔ FTC: ↔ TFV: ↑40% |
| DRV/r+FTC/TDF | SOF: ↓28% GS-331007: ↔ VEL: ↔ | DRV: ↔ RTV: ↔ FTC: ↔ TFV: ↑40% |
| ATV/r+FTC/TDF | SOF: ↔ GS-331007: ↔ VEL: ↑142% | ATV: ↔ RTV: ↔ FTC: ↔ TFV: ↔ |
| LPV/r+FTC/TDF | SOF: ↓29% GS-331007: ↔ VEL: ↔ | LPV: ↔ RTV: ↔ FTC: ↔ TFV: ↔ |
| EVG/COBI/FTC/TDF | SOF: ↔ GS-331007: ↔ VEL: ↔ | EVG: ↔ COBI: ↔ FTC: ↔ TFV: ↔ |
| EVG/COBI/FTC/TAF | SOF: ↑37% GS-331007: ↑48% VEL: ↑50% | EVG: ↔ COBI: ↔ FTC: ↔ TAF: ↔ TFV: ↔ |